Abivax Temporarily Halts Trading on Euronext Paris

Abivax, a clinical-stage biotechnology firm, has announced a temporary halt in the trading of its ordinary shares on Euronext Paris. The trading suspension, requested by the company, began at the market's opening on July 24, 2025. This move is linked to the company's public offering of American Depositary Shares in the United States. The temporary halt aims to facilitate the confirmation of allocations to investors and announce the offering's pricing.

The company anticipates resuming trading on the same day at approximately 3:30 p.m. CEST. Abivax focuses on developing therapies targeting the immune response in chronic inflammatory disease patients. The suspension is set to end upon a forthcoming communication by the company.